News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 528 results

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

30-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals have announced that nine…

alirocumabCardio-vascularGeorge YancopoulosPharmaceuticalResearchSanofiUSA

Zealand and Boehringer link up to advance novel peptide medicines

Zealand and Boehringer link up to advance novel peptide medicines

28-07-2014

Denmark’s Zealand Pharma has entered into a new global exclusive licence and R&D collaboration with…

Boehringer IngelheimCardio-vascularDenmarkFinancialGermanyLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

23-07-2014

Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

UK's NICE changes guidance to recommend Eli Lilly’s Efient for blood clots

23-07-2014

The National Institute for Health and Care Excellence (NICE), the UK’s health care guidance body, has…

Acute coronary syndromesCardio-vascularEfientEli LillyPharmaceuticalprasugrelRegulationUK

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

Milestone appoints Francis Plat as chief medical officer

Milestone appoints Francis Plat as chief medical officer

21-07-2014

Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment…

BoardroomCanadaCardio-vascularFrancis PlatMilestone PharmaceuticalsPharmaceutical

Impax Labs receives subpoena over digoxin

Impax Labs receives subpoena over digoxin

16-07-2014

US generic drugmaker Impax Laboratories revealed in a Securities Exchange Commission filing that, on…

Cardio-vascularCardiologydigoxinGenericsImpax LaboratoriesLegalMarkets & MarketingUSA

Servier to appeal EC fine over perindopril

Servier to appeal EC fine over perindopril

11-07-2014

French privately-held drugmaker Servier has said it will appeal before the European Union Court of Justice…

Cardio-vascularEuropeFinancialLegalPerindoprilperindoprilPharmaceuticalServier

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

Portola in second deal with Daiichi Sankyo for Factor Xa inhibitor antidote

10-07-2014

USA-based Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Japanese…

andexanet alfaCardio-vascularDaiichi SankyoedoxabanJapanLicensingPharmaceuticalPortola PharmaceuticalsResearchSavaysaUSA

Regado Biosciences announces FDA’s clinical hold of Ph III trial

Regado Biosciences announces FDA’s clinical hold of Ph III trial

10-07-2014

The US Food and Drug Administration (FDA) has informed US-based cardiovascular specialist Regado Biosciences…

Acute coronary syndromeBiotechnologybivalirudinCardio-vascularMedicineRegadoRegulationUSA

Proveca reaches agreement with EMA over heart failure drug for children

Proveca reaches agreement with EMA over heart failure drug for children

10-07-2014

UK pharmaceutical company Proveca has reached its fourth key agreement with the European Medicines Agency…

CaptoprilCardio-vascularPharmaceuticalRegulationUK

European Generic Medicines Association speaks out against EC’s perindopril decision

European Generic Medicines Association speaks out against EC’s perindopril decision

09-07-2014

The European Generic Medicines Association (EGA) has expressed concerns over the European Commission’s…

Cardio-vascularEuropeGenericsLegalLupinperindoprilServierunichem

Mylan launches generic Micardis in USA

Mylan launches generic Micardis in USA

08-07-2014

US generic drugmaker Mylan has launched Telmisartan Tablets USP, 20mg, 40mg and 80mg, the generic version…

Boehringer IngelheimCardio-vascularGenericsMarkets & MarketingMicardisMylanRegulationTelmisartanUSA

AstraZeneca in research accord with Max Planck Institute

AstraZeneca in research accord with Max Planck Institute

08-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement with the Max Planck Institute of Molecular…

AstraZenecaCardio-vascularMetabolicsPharmaceuticalResearch

Pozen re-files for US approval of PA8140/PA32540

Pozen re-files for US approval of PA8140/PA32540

02-07-2014

US drug firm Pozen has resubmitted the New Drug Application for PA8140/PA32540 (aspirin and omeprazole)…

AspirinCardio-vascularOmeprazolePA8140/PA32540PharmaceuticalPozenRegulationUSA

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

Ivabradine and CV events in angina patients under review in Australia

Ivabradine and CV events in angina patients under review in Australia

23-06-2014

Australian pharma regulator the Therapeutic Goods Administration (TGA) is reviewing new information regarding…

AustraliaCardio-vascularCoralanivabradinePharmaceuticalRegulationServier

1 to 25 of 528 results

Back to top